Date: 2015-04-09
Type of information: Subvention
Company: Antabio (France)
Investors: BpiFrance (France)
Amount: € 1 million
Funding type: subvention
Planned used: The funds will be used to discover compounds targeting key mechanisms of bacterial pathogenicity that will be co-administered with antibiotics to enhance their effectiveness against multi drug-resistant bacteria that cause severe human and animal diseases. With the renewed support of Bpifrance, Antabio will continue to extend and progress its drug discovery programmes, aimed at delivering preclinical candidates that will be taken to clinical proof of concept studies by Antabio and its future development partners.
Others: * On April 9, 2015, Antabio and Bpifrance announce that Antabio will receive € 1 million in funding to support its Antibiotic Adjuvant Factory dedicated to the discovery and development of new antibacterial treatments. This new funding follows an initial grant of € 742,000 received from Bpifrance in 2013 to support the setup of the Factory, which led to the rapid advancement of several drug discovery programmes within the company. Antabio’s discovery programmes are supported by the Wellcome Trust, Bpifrance (the French Public Investment bank), and the Concours Mondial de l’Innovation 2030 and are focused on the development of novel inhibitors of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and first-in-class inhibitors of Pseudomonas biofilms for the long-term management of chronic respiratory infections. www.antabio.com
Therapeutic area: Infectious diseases
